Search results for: symetis

Need a new search

If you didn't find what you were looking for, try a new search!

Symetis launches its IPO on Euronext Paris

Symetis launches its IPO on Euronext Paris Symetis develops, produces and markets heart valve replacement solutions for the treatment of severe cardiac valve conditions. The company plans to raise € 55.8 million that could be increased to approximately € 64.1 [...]

2022-03-22T15:43:29+00:00March 20th, 2017|

Symetis launches €55M IPO for artificial heart valves

Symetis launches €55M IPO for artificial heart valves The Swiss medtech company Symetis has launched a €55M IPO to accelerate the development of its next-generation heart valve replacement solutions. Symetis develops next-generation heart valve replacements for the treatment of cardiac [...]

2022-03-22T15:43:50+00:00March 20th, 2017|

Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo™, and Launches Product With First Commercial Implantations

Symetis Receives CE Mark Approval for Transfemoral Transcatheter Aortic Heart Valve System ACURATE neo™, and Launches Product With First Commercial Implantations Symetis Joins Industry Leaders Edwards Lifesciences and Medtronic as Only Companies to Offer Both Transapical and Transfemoral Options for [...]

2022-03-22T15:52:55+00:00September 12th, 2014|
Go to Top